Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 15, 2022
Reporting Period: Second quarter ended June 30, 2022
Business Context: The filing serves as a notification of the Company's announcement of financial results for the second quarter of 2022. The full details of the results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt
- Liquidity
Note: The filing text does not provide a clear value for any financial metric; these figures are located in the referenced Exhibit 99.1 (Press Release).
Material Changes
The filing text does not disclose specific material changes versus the prior comparable period. It only confirms that financial results for the quarter ended June 30, 2022, were announced on August 15, 2022.
Guidance, Outlook, and Risks
The provided text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. The document explicitly states that the information regarding results is furnished and not "filed" for purposes of Section 18 of the Exchange Act, directing readers to the attached press release for details.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 15, 2022) for actual revenue, net loss, and cash position figures.
- Verify the Company's status as an Emerging Growth Company (indicated as checked in the filing) and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbol IDYA on The Nasdaq Global Select Market.
- Check for any subsequent filings that may provide updated liquidity or debt covenants not detailed in this summary.